
## Mano Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2729834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. Journal of Investigative Dermatology, 2022, 142, 726-731.e4.	0.7	2
2	Combined antiâ€PDâ€1 and anti TLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanis of action. European Journal of Immunology, 2021, 51, 544-556.	ims 2.9	71
3	lgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. Cancers, 2020, 12, 3376.	3.7	15
4	IgE Antibodies against Cancer: Efficacy and Safety. Antibodies, 2020, 9, 55.	2.5	17
5	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells, 2020, 9, 1631.	4.1	26
6	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2020, 11, 622442.	4.8	39
7	Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer. Cancer Research, 2020, 80, CT141-CT141.	0.9	13
8	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. OncoImmunology, 2019, 8, e1593811.	4.6	20
9	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	4.8	177
10	Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling. Cancer Research, 2017, 77, 1127-1141.	0.9	58
11	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget, 2017, 8, 78174-78192.	1.8	75
12	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. Frontiers in Immunology, 2017, 8, 1911.	4.8	87